breast cancer

Two independent research groups have found that simultaneous inhibition of two signaling pathways -- mTOR and MAPK signaling pathways -- results in substantially enhanced antitumor effects when compared with inhibition of either pathway alone in mouse models of prostate and breast cancer.

Scientists have identified a way to "switch off" a molecule, a key player in the molecular processes that trigger breast cancer and certain forms of leukaemia.

Whether a painless, portable device that uses electrical current rather than X-ray to look for breast cancer could be an alternative to traditional mammograms is under study.

New research will compare traditional mammograms to impedence scanning, a technique based on evidence that electrical current passes through cancerous tissue differently than through normal tissue.

Recently identified genetic markers, called single nucleotide polymorphisms, that are associated with a small but statistically significant increase in the risk of breast cancer do not appear to substantially improve the accuracy of existing models that use clinical factors to predict an individual's risk, according to a new study in the Journal of the National Cancer Institute.

(University of Illinois at Urbana-Champaign) Researchers have discovered a new family of agents that inhibit the growth of estrogen-dependent breast cancer cells.

The finding, described today at a meeting of the Endocrine Society, has opened an avenue of research into new drugs to combat estrogen-dependent breast cancers.

Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer, according to a Phase II clinical trial led by researchers.

Maintaining bone density could be a key to decreasing the spread of cancer in women with locally advanced breast cancer, according to new research.

Bones are common sites for the spread, or metastasis, of breast cancer. Scientists have found that women treated for stage II/III breast cancer who also received a bone strengthening drug were less likely to have breast tumor cells growing in their bones after three months.

A chemical reaction in genes that control breast cancer provides a molecular clock that could one day help researchers more accurately determine a woman's risk for developing breast cancer and provide a new approach for treatment.

Physically active women are 25 percent less likely to get breast cancer, but certain groups are more likely to see these benefits than others, finds a review in the British Journal of Sports Medicine.

The type of activity undertaken, at what time in life and the woman's body mass index (BMI) will determine how protective the activity is against the disease.

Scientists have made a significant discovery that clarifies a previously poorly understood key event in the progression of breast cancer.

The research highlights the importance of the microenvironment in regulating breast tumor progression and suggests that it may be highly beneficial to consider therapies that do not focus solely on the tumor cells but are also targeted to the surrounding tissues.